文献速递青光眼

原发性开角型青光眼多基因风险评分与疾病发病风险:一项随机临床试验的事后分析

Primary Open-Angle Glaucoma Polygenic Risk Score and Risk of Disease Onset: A Post Hoc Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2024-11-07

该研究为高眼压治疗研究(OHTS)的事后分析,纳入1010例有遗传数据的欧裔或非裔高眼压参与者,评估原发性开角型青光眼多基因风险评分(PRS)识别低发病风险个体的效用。在中位20年随访中,PRS低于第48百分位与无病状态可能性升高相关(校正后1.49倍,95%CI 1.04-2.15,P=0.03)。在OHTS临床风险最高三分位初始观察组中,高多基因风险组20年转化率为61.1%,低多基因风险组为23.8%(95%CI -63.0至-11.6,P=0.01);早期治疗可部分减轻高遗传风险的影响。

要点

  • PRS低于第48百分位与20年无病状态可能性升高相关(校正后1.49倍,95%CI 1.04-2.15,P=0.03)。
  • 在OHTS临床风险最高三分位初始观察组,高多基因风险组20年转化率61.1%,低多基因风险组23.8%(P=0.01)。
  • 在最高三分位早期治疗组,高多基因风险组20年转化率37.3%,低多基因风险组24.1%(P=0.32)。

核心结论

  • 这些发现支持考虑使用POAG PRS阈值来识别疾病发病低风险的个体,低于PRS阈值者在20年内转化率更低。
  • 在基于OHTS临床风险模型被认为最高风险者中,早期治疗可能部分抵消高遗传风险的关联,但对低遗传风险者获益有限。

研究设计与样本

  • 本研究为高眼压治疗研究(OHTS)的事后分析,OHTS是一项在美国22个中心开展的多中心随机临床试验,1994年2月至2019年4月纳入1636例高眼压参与者。
  • 1636例原始参与者中1077例有可用遗传数据;排除67例因数据缺失、数据质量问题或非欧裔/非裔祖源后,1010例纳入本分析。
  • 本报告数据分析时间为2023年11月至2024年6月。

主要发现

  • 1010例参与者中563例(65.8%)为女性,平均(SD)年龄55.9(9.4)岁。
  • 在调整OHTS转化危险因素和随机化状态的混合效应逻辑回归模型中,与高多基因风险相比,PRS低于第48百分位与20年随访后无病状态可能性升高1.49倍相关(95%CI 1.04-2.15;P=0.03;未校正风险比[HR]1.64;95%CI 1.13-2.38;P=0.009)。
  • 将试验队列按非遗传OHTS临床风险三分位分层后,基于PRS阈值的20年生存概率最大差异见于最高三分位初始观察组(20年转化率:高多基因风险组61.1% vs 低多基因风险组23.8%;95%CI -63.0至-11.6;P=0.01)。
  • 在最高三分位早期治疗组,随机化至早期治疗部分减轻高遗传风险的影响(20年转化率:高多基因风险组37.3% vs 低多基因风险组24.1%;95%CI -35.6至9.3%;P=0.32)。

临床怎么用

  • 原文结论支持考虑使用POAG PRS阈值来识别疾病发病低风险的个体,低于PRS阈值者20年内转化率更低。
  • 在基于OHTS临床风险模型被认为最高风险者中,早期治疗可能部分抵消高遗传风险的关联,但对低遗传风险者获益有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Primary open-angle glaucoma (POAG) is a heritable disease. A polygenic risk score (PRS) threshold may be used to identify individuals at low risk of disease onset. OBJECTIVE: To assess the utility of a POAG PRS to identify ocular hypertensive individuals at low risk of disease onset. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc analysis of the Ocular Hypertension Treatment Study (OHTS), a multicenter randomized clinical trial across 22 centers in the US conducted among 1636 participants with ocular hypertension from February 1994 to April 2019 with available genetic data. Of the 1636 original participants, 1077 had available genetic data; after excluding 67 for missing data, data quality concerns, or ancestry other than European or African, 1010 were included in the present analysis. Data for this report were analyzed from November 2023 to June 2024. EXPOSURE: From 1994-2002, participants were randomized to receive topical intraocular pressure (IOP)-lowering medications. From 2002 onwards, all participants were given topical IOP-lowering medications. MAIN OUTCOME AND MEASURE: Twenty-year conversion rates by POAG PRS threshold, baseline randomization status, and OHTS clinical risk tertile. RESULTS: Among the 1010 participants in this study, 563 (65.8%) were female, and the mean (SD) age was 55.9 (9.4) years. In a mixed-effects logistic regression model adjusted for OHTS risk factors for conversion to POAG and randomization status, a PRS under the 48th percentile was associated with a 1.49 times higher likelihood of disease-free status after 20 years of follow-up (95% CI, 1.04-2.15; P = .03; unadjusted hazard ratio [HR], 1.64; 95% CI, 1.13-2.38; P = .009), compared with high polygenic risk. When we stratified the trial cohort into nongenetic OHTS clinical risk tertiles, the largest differences in survival probability at 20 years based on PRS threshold was observed in eyes in the highest tertile, initial observation group (20-year conversion rate: 61.1% in the high polygenic risk group vs 23.8% in the low polygenic risk group; 95% CI, -63.0 to -11.6; P = .01), with randomization to early treatment partially mitigating the effect of high genetic risk (20-year conversion rate: 37.3% in the high polygenic risk group vs 24.1% in the low polygenic risk group; 95% CI, -35.6 to 9.3%; P = .32). CONCLUSIONS AND RELEVANCE: These findings support considering use of a POAG PRS threshold to identify individuals at low risk of disease onset, with those below the PRS threshold more likely to have lower conversion rates over 20 years. Among those considered at highest risk based on the OHTS clinical risk model, early treatment may partially offset the association with high genetic risk but provide limited benefit for those with low genetic risk. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00000125.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sekimitsu S, Ghazal N, Aziz K, et al. Primary Open-Angle Glaucoma Polygenic Risk Score and Risk of Disease Onset: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2024. PMID: 39509108. doi:10.1001/jamaophthalmol.2024.4376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。